Metraipolis › archive › dc_436bfb764178
Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy — Europe PMC PMID:41267925
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41267925
- DOI
- 10.1002/mco2.70500
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T11:52:54.715Z
- SHA-256 of the archived text
b2b7545a2d9eb7a91482749ab99626bd629773cd98f6c93c98a02db82cdaf7ac- Stable URL of this page
https://metraipolis.com/documento/dc_436bfb764178
How to cite
Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy — Europe PMC PMID:41267925 — Europe PMC (en), https://europepmc.org/article/MED/41267925 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_436bfb764178 (Metraipolis archive dc_436bfb764178, sha256 b2b7545a2d9eb7a91482749ab99626bd629773cd98f6c93c98a02db82cdaf7ac)
BibTeX
@misc{dc436bfb764178,
title = {Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy — Europe PMC PMID:41267925},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41267925},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_436bfb764178; sha256 b2b7545a2d9eb7a91482749ab99626bd629773cd98f6c93c98a02db82cdaf7ac},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41267925. Agents can read the archived copy with the MCP tool read_document.